Michael Fuchs

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Topics

Hodgkin Lymphoma

Radiation Induced

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Oertel, Priska Hölscher, Dominik Alexander Hering, Christopher Kittel, Michael Fuchs, Uwe Haverkamp, Peter Borchmann, Hans Theodor Eich
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group. Cancers 16 (6) (2024)
Michael Oertel, Priska Hölscher, Dominik Alexander Hering, Christopher Kittel, Michael Fuchs, Uwe Haverkamp, Peter Borchmann, Hans Theodor Eich
Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma-A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group. Cancers 16 (6) (2024)
Dennis A Eichenauer, Michael Fuchs
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? Cancers 15 (13) (2023)
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (6) (2022)
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (6) (2022)
Paul J Bröckelmann, Ina Bühnen, Julia Meissner, Karolin Trautmann, Peter Herhaus, Teresa V Halbsguth, Valdete Schaub, Andrea Kerkhoff, Stephan Mathas, Matthias Bormann, Andreas Dickhut, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert, Bastian von Tresckow
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Paul J Bröckelmann, Horst Müller, Teresa Guhl, Karolin Behringer, Michael Fuchs, Alden A Moccia, Andreas Rank, Martin Soekler, Tom Vieler, Thomas Pabst, Christian Baues, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (2) (2020)